Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Neuromodulation for Functional Recovery After Stroke (VNS-EARLY)

20 septembre 2026 mis à jour par: Xuanwu Hospital, Beijing

This study used a multicenter, double-blind, randomized controlled design. The trial protocol was jointly designed by the principal investigator and an executive committee composed of experts in functional neurosurgery, cerebrovascular disease, and rehabilitation medicine. The study enrolled patients in the subacute phase (3-6 months) after ischemic stroke with upper limb motor impairment. All patients were implanted with a vagus nerve stimulation (VNS) device and randomly assigned to an active VNS (0.8 mA) group combined with upper limb rehabilitation or a control VNS (0.0 mA) group.

This study used the FMA-UE score, WMFT score, and other measures to assess changes in impairment severity. The primary endpoint was the difference in FMA-UE score between the active VNS group and the control group at the end of 6 weeks of hospital treatment. Secondary endpoints included changes from baseline in FMA-UE score and WMFT score at 90 days, among others. This study evaluates the safety and efficacy of vagus nerve stimulation for improving upper limb motor function in patients in the subacute phase after stroke, ultimately providing clinical evidence for the diagnosis and treatment of this patient population.

Aperçu de l'étude

Description détaillée

This study uses a multicenter, double-blind, randomized controlled design. Eligible participants all undergo implantation of a VNS device and are randomly assigned to an active VNS (0.8 mA) group combined with upper limb rehabilitation or a control VNS (0.0 mA) group. The study hypothesizes that vagus nerve stimulation is effective in improving upper limb motor function in patients in the subacute phase after stroke; that is, a meaningful difference in FMA-UE scores exists between the active VNS group and the control group at the end of 6 weeks of hospital treatment. All enrolled participants undergo implantation of a vagus nerve stimulation device. After preoperative assessment, patients undergo implantation of the vagus nerve stimulation device under general anesthesia. After implantation, participants are randomized 1:1 to active VNS (0.8 mA) combined with upper limb rehabilitation or control VNS (0.0 mA). This trial uses the FMA-UE score, WMFT score, and other measures to assess changes in impairment severity, with a pretreatment baseline assessment performed 1 week after implantation. Stimulation testing is performed in 0.1 mA increments in both groups to assess the level at which participants can perceive and tolerate stimulation. Hospital treatment begins on the day after baseline assessment.

Type d'étude

Interventionnel

Inscription (Estimé)

100

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Xuesong Bai, Dr.
  • Numéro de téléphone: 86 18810032664
  • E-mail: bxsben@163.com

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 80 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. History of unilateral supratentorial ischemic stroke and in the subacute phase (3-6 months);
  2. Age between 18-80 years, both male and female;
  3. FMA-UE score of 20-50 (inclusive);
  4. Ability to communicate, understand, and provide appropriate consent; participant can follow two-step commands;
  5. Right or left upper limb weakness;
  6. Active flexion/extension of the wrist or fingers;
  7. Informed consent signed by the patient or a family member.

Exclusion Criteria:

  1. History of hemorrhagic stroke;
  2. Persistent dysphagia or choking/coughing while eating or drinking;
  3. Medications that, at study initiation, may significantly interfere with the effects of VNS on neurotransmitter systems;
  4. Prior vagus nerve injury, bilateral or unilateral (e.g., injury during carotid endarterectomy);
  5. Severe or more severe depression (Beck Depression Inventory >29);
  6. Candidates unsuitable for device implantation surgery (e.g., history of adverse reaction to anesthesia, deemed unsuitable as a surgical candidate by the surgeon, etc.);
  7. Current use of any other stimulation device, such as a pacemaker or other neurostimulator; current use of any other investigational device or drug;
  8. Preexisting neurological or psychiatric disorders before stroke onset that affect assessment of the condition;
  9. Pregnancy, planned pregnancy, or breastfeeding during the study period;
  10. Severe upper limb spasticity (modified Ashworth ≥3);
  11. Severe sensory loss. Sensory loss will be measured using the upper extremity sensory portion of the Fugl-Meyer Assessment. The assessment involves light touch (two items) and proprioception (four items). The maximum score is 12; subjects with a score below 6 will be excluded from the study;
  12. Other conditions that the investigator considers unsuitable for participation or that may pose a significant risk to the patient.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Active VNS group

After implantation, participants randomized to active VNS (0.8 mA) combined with upper limb rehabilitation.

After implantation, participants are randomized 1:1 to active VNS (0.8 mA) combined with upper limb rehabilitation or control VNS (0.0 mA). To reduce the risk of participants inferring treatment assignment, participants in both treatment groups receive five stimuli of decreasing intensity at the beginning of each treatment session (starting at 0.8 mA and then decreasing by 0.1 mA at each step), after which treatment is administered according to randomization.

Comparateur factice: Control VNS group

After implantation, participants randomized to control VNS (0 mA) combined with upper limb rehabilitation.

After implantation, participants randomized to Control VNS (0.8 mA) combined with upper limb rehabilitation.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
The difference in Fugl-Meyer Assessment-Upper Extremity (FMA-UE) scores between the active VNS group and the control group at the end of 6 weeks of hospital treatment.
Délai: At the end of 6 weeks of hospital treatment.

The FMA-UE total score ranges from 0 to 66, with higher scores indicating better upper-extremity motor function.

At the end of 6 weeks of hospital treatment.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Clinically meaningful improvement in Fugl-Meyer Assessment-Upper Extremity (FMA-UE) at 90 days (≥6-point improvement in FMA-UE score);
Délai: 90 days

The FMA-UE total score ranges from 0 to 66, with higher scores indicating better upper-extremity motor function.

90 days
Change from baseline in Wolf Motor Function Test (WMFT) score at 90 days
Délai: 90 days

The WMFT Functional Ability Scale ranges from 0 to 75, with higher scores indicating better upper-extremity function.

90 days
Change from baseline in Fugl-Meyer Assessment-Upper Extremity (FMA-UE) at 90 days
Délai: 90 days

The FMA-UE total score ranges from 0 to 66, with higher scores indicating better upper-extremity motor function.

90 days

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Change from baseline in Stroke Impact Scale (SIS) score at 90 days
Délai: 90 days

The SIS score ranges from 0 to 100, with higher scores indicating better health status and functioning.

90 days
Change from baseline in Stroke-Specific Quality of Life (SS-QOL) score at 90 days
Délai: 90 days

The SS-QOL total score ranges from 49 to 245, with higher scores indicating better quality of life.

90 days
Change from baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) utility index score at 90 days
Délai: 90 days

The EuroQol 5-Dimension 5-Level utility index ranges from -0.391 to 1.000, with higher scores indicating better health-related quality of life.

90 days
Change from baseline in Motor Activity Log (MAL) score at 90 days
Délai: 90 days

Each MAL subscale ranges from 0 to 5, with higher scores indicating better real-world use and movement quality of the affected upper extremity.

90 days
Change from baseline in Beck Depression Inventory (BDI) total score at 90 days
Délai: 90 days

The BDI total score ranges from 0 to 63, with higher scores indicating more severe depressive symptoms and therefore a worse outcome.

90 days
Adverse events: adverse events occurring during the study period (including the surgical procedure);
Délai: From study enrollment through the Day 90 follow-up visit, including the perioperative period.
From study enrollment through the Day 90 follow-up visit, including the perioperative period.
Device complications: any unexpected adverse reactions of the device
Délai: From device implantation through the Day 90 follow-up visit.
From device implantation through the Day 90 follow-up visit.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

  • 1. 王拥军, et al., 中国卒中报告2019(中文版)(1). 中国卒中杂志, 2020. 15(10): p. 1037-1043. 2. Nakayama, H., et al., Recovery of upper extremity function in stroke patients: The Copenhage n stroke study. Archives of Physical Medicine and Rehabilitation. 75(4): p. 394-398. 3. Opara, J.A. and K. Jaracz, Quality of life of post-stroke patients and their caregivers. J Med Life, 2010. 3(3): p. 216-20. 4. Butt, M.F., et al., The anatomical basis for transcutaneous auricular vagus nerve stimulation. J Anat, 2020. 236(4): p. 588-611. 5. van der Meij, A. and M.J.H. Wermer, Vagus nerve stimulation: a potential new treatment for ischaemic strok e. Lancet (London, England). 397(10284): p. 1520-1521. 6. Ay, I., et al., Transcutaneous Cervical Vagus Nerve Stimulation Ameliorates Acute Isch emic Injury in Rats. Brain stimulation. 9(2): p. 166-73. 7. Kimberley, T.J., et al., Vagus Nerve Stimulation Paired With Upper Limb Rehabilitation After Ch ronic Stroke. Stroke. 49(11): p. 2789-2792. 8. Dawson, J., et al., Safety, Feasibility, and Efficacy of Vagus Nerve Stimulation Paired With Upper-Limb Rehabilitation After Ischemic Stroke. Stroke, 2016. 47(1): p. 143-50. 9. Dawson, J., et al., Vagus nerve stimulation paired with rehabilitation for upper limb motor function after ischaemic stroke (VNS-REHAB): a randomised, blinded, pivotal, device trial. Lancet, 2021. 397(10284): p. 1545-1553. 10. Grefkes, C. and G.R. Fink, Recovery from stroke: current concepts and future perspectives. Neurological Research and Practice, 2020. 2(1): p. 17.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

30 octobre 2026

Achèvement primaire (Estimé)

1 septembre 2028

Achèvement de l'étude (Estimé)

1 décembre 2028

Dates d'inscription aux études

Première soumission

13 septembre 2026

Première soumission répondant aux critères de contrôle qualité

20 septembre 2026

Première publication (Réel)

25 septembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

25 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

20 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

The VNS-EARLY Steering Committee will consider on a case-by-case basis requests for data sharing.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner